Airsculpt Technologies Inc (AIRS) is at the forefront of the aesthetic medical technology sector, specializing in its proprietary AirSculpt® procedure, which sets a new standard for minimally invasive body contouring while prioritizing patient safety and comfort. The company is aggressively expanding its network of licensed practitioners and utilizing innovative technologies to solidify its competitive advantage in the rapidly growing non-invasive cosmetic treatment market. With rising global demand for aesthetic solutions, Airsculpt is well-positioned to capture market share and broaden its service offerings, driving robust growth and long-term value for its investors.
| Revenue (TTM) | $150.72M |
| Gross Profit (TTM) | $99.93M |
| EBITDA | $6.29M |
| Operating Margin | -0.07% |
| Return on Equity | -12.00% |
| Return on Assets | -1.91% |
| Revenue/Share (TTM) | $2.28 |
| Book Value | $1.47 |
| Price-to-Book | 1.75 |
| Price-to-Sales (TTM) | 1.34 |
| EV/Revenue | 1.558 |
| EV/EBITDA | 267.32 |
| Quarterly Earnings Growth (YoY) | 200.00% |
| Quarterly Revenue Growth (YoY) | -2.50% |
| Shares Outstanding | $72.09M |
| Float | $16.77M |
| % Insiders | 42.14% |
| % Institutions | 63.36% |
Volatility is currently expanding
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. ("AirSculpt" or the "Company") (NASDAQ: AIRS).
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. ("AirSculpt" or the "Company") (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
AirSculpt Technologies, Inc. (AIRS) Q2 2026 Earnings Call Transcript
AirSculpt Technologies NASDAQ: AIRS reported second-quarter revenue of $42.9 million, down 2.5% from the prior-year period, as the company cited stable revenue trends, positive same-center case growth and continued investment in marketing and expanded procedure offerings.
MIAMI BEACH, Fla., Aug. 10, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the second quarter ended June 30, 2026.
Company to Participate in Canaccord Genuity's 46th Annual Growth Conference Company to Participate in Canaccord Genuity's 46th Annual Growth Conference
HONG KONG & SEOUL, South Korea--(BUSINESS WIRE)--AIRS Medical (“the Company”), a global leader in AI solutions for medical imaging, today announced a strategic growth investment from TA Associates (“TA”), a leading global private equity firm. The investment will help fuel AIRS Medical's next phase of global expansion, advancement of its AI-powered radiology technology solutions and ongoing product innovation. Founded in 2018, AIRS Medical develops AI-native magnetic resonance imaging (“MRI”) ac.
MIAMI BEACH, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS), an industry leader and provider of premium body contouring procedures, today announced that the Company will participate in upcoming investor conferences.
AirSculpt Technologies, Inc. (AIRS) Shareholder/Analyst Call Prepared Remarks Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AIRS and any ticker you trade — then tracks every position and per-strategy win rate.
